HOME >> MEDICINE >> NEWS
Study Leads To New Standard Of Care For Treating Unstable Angina: Heart-Attack,,Risk Reduced By 47% With Use Of Tirofiban

A major international study by cardiologists has shown that the addition of tirofiban into the medical management of patients with unstable angina reduces their risk of death by as much as 47%. Unstable angina is currently the leading cause of admissions to coronary care units, accounting for more than 1.4 million hospitalizations per year in the United States. Tirofiban, a member of a new class of anti-platelet inhibitors, proved so effective in decreasing the incidence of post-angina heart-attacks that the researchers recommended its use as part of a new therapeutic standard of care. The researchers' study and clinical recommendation will be published in the May 21 issue of The New England Journal of Medicine.

Unstable angina is a life-threatening cardiac condition that occurs when bloodflow to the heart muscle is disrupted or impaired. In most cases, the pain of angina is associated with the rupturing of large cholesterol plaques that have built-up, over time, near the outer walls of the heart chamber. "At the present time, we treat this condition with a combination of heparin and aspirin because both of those drugs have unique properties that encourage the dissolution of plaques," explains Howard Herrmann, MD, associate professor of medicine at the University of Pennsylvania Medical Center -- one of the 72 participating trial sites. "Our study showed that the intravenous introduction of tirofiban into the standard treatment protocol provides additional benefit to patients because tirofiban helps prevent the development of plaque deposits by blocking the aggregation of platelets -- which is a precursor to clot development."

In their two-year investigation of 1,915 patients with unstable angina or non-Q-wave myocardial infarction (which represents the middle ground, clinically speaking, between angina and a full-blown heart attack), the researchers tested the effectiveness of tirofiban in addition to heparin and aspirin [PRISM-PLUS]
'"/>

Contact: Rebecca Harmon
harmonr@mail.med.upenn.edu
215-349-5660
University of Pennsylvania School of Medicine
21-May-1998


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics (ACMI) will ... during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual ... F. Collen, a pioneer in the field of medical informatics, this prestigious award is ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health ... Miles by Moonlight to raise money for the American Heart Association Heart Walk. Teams ... Teams will work together to keep their treadmills moving for 5 hours. Treadmills will ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy ... health literacy software tool, and the Cancer Patient Education Network (CPEN), an independent ... today announce a new strategic alliance. , As CPEN’s strategic partner, HLI ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... -- AllianceRx Walgreens Prime, the combined central specialty pharmacy and ... manager Prime Therapeutics LLC (Prime), today officially began the ... of new signage at its headquarters in ... few other company-owned facilities across the country. This also ... whom will begin to see the AllianceRx Walgreens Prime ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans Bioscience ... the use of wearable and home sensors for real-time ... Early Signal Foundation, a nonprofit organization focused on disruptive ... provide an affordable analytical system to record and integrate ... ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology:
Cached News: